SELENIOUS ACID INJECTION, USP DIN 02558254
Status: Approved
Holder: FRESENIUS KABI CANADA LTD
Health Canada record
| Active ingredient(s) | SELENIUM (SELENIOUS ACID) 60 MCG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | ETHICAL |
|---|
| Class | Human |
|---|
| ATC | A12CX OTHER MINERAL PRODUCTS |
|---|
| Original market date | |
|---|
| Current status date | 03-Jun-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Fresenius Kabi Canada Ltd. — licence 102232, currently licensed, last inspection rating C (2025-10-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SELENIUM (SELENIOUS ACID)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 01986007 | MICRO SE | SANDOZ CANADA INCORPORATED | Solution | SELENIUM (SELENIOUS ACID) 40 MCG | Marketed |
| 02139316 | SELEPEN | PHARMACEUTICAL PARTNERS OF CANADA INC | Solution | SELENIUM (SELENIOUS ACID) 40 MCG | Cancelled Post Market |
| 01945335 | SELEPEN INJ 40MCG/ML USP | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | Liquid | SELENIUM (SELENIOUS ACID) 40 MCG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 35466 | 2025-06-03 | Abbreviated New Drug Submission (ANDS) | |
Request a quote for SELENIOUS ACID INJECTION, USP
How to read a Canadian DIN record